A Diagnostics & Imaging Week

Veridex (Warren, New Jersey) reported signing an exclusive, global license agreement with OncoMethylome Sciences (Liege, Belgium) for molecular prostate cancer assays. In addition, both parties have agreed on a development program and an option to license additional assays in the prostate cancer field.

Financial details of the agreement have not been disclosed.

"We are excited by the prospect of applying our expertise in molecular diagnostics to the prostate cancer field," said Mark Myslinski, general manager of Veridex. "With the technology licensed from OncoMethylome Sciences, we hope to develop high-value assays that will improve the diagnostic process for physicians and patients."

Veridex is a Johnson & Johnson (New Brunswick, New Jersey) company.

No Comments